A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of intratumoral administration of T-VEC as monotherapy for inoperable locoregional recurrence of breast cancer. T-VEC was injected intratumorally at 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kai, Megumi, Marx, Angela N., Liu, Diane D., Shen, Yu, Gao, Hui, Reuben, James M., Whitman, Gary, Krishnamurthy, Savitri, Ross, Merrick I., Litton, Jennifer K., Lim, Bora, Ibrahim, Nuhad, Kogawa, Takahiro, Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593093/
https://www.ncbi.nlm.nih.gov/pubmed/34782633
http://dx.doi.org/10.1038/s41598-021-01473-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593093/
https://www.ncbi.nlm.nih.gov/pubmed/34782633
http://dx.doi.org/10.1038/s41598-021-01473-2

Ejemplares similares